These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 37406511)

  • 1. IPSC-derived CAR-NK cells for cancer immunotherapy.
    Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G
    Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.
    Rafei H; Daher M; Rezvani K
    Br J Haematol; 2021 Apr; 193(2):216-230. PubMed ID: 33216984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
    Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
    Li Y; Hermanson DL; Moriarity BS; Kaufman DS
    Cell Stem Cell; 2018 Aug; 23(2):181-192.e5. PubMed ID: 30082067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
    Goldenson BH; Hor P; Kaufman DS
    Front Immunol; 2022; 13():841107. PubMed ID: 35185932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells.
    Klaihmon P; Kang X; Issaragrisil S; Luanpitpong S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
    Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
    Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-NK Cells: From Natural Basis to Design for Kill.
    Khawar MB; Sun H
    Front Immunol; 2021; 12():707542. PubMed ID: 34970253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering Natural Killer Cells for Cancer Immunotherapy.
    Rezvani K; Rouce R; Liu E; Shpall E
    Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
    Nguyen S; Lacan C; Roos-Weil D
    Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic stem cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions.
    Arias J; Yu J; Varshney M; Inzunza J; Nalvarte I
    Stem Cells Transl Med; 2021 Jul; 10(7):987-995. PubMed ID: 33634954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells.
    Tang SY; Zha S; Du Z; Zeng J; Zhu D; Luo Y; Wang S
    Stem Cell Res Ther; 2021 Nov; 12(1):580. PubMed ID: 34802459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
    Wang W; Jiang J; Wu C
    Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
    Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
    Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
    Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
    Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors.
    Ueda T; Kaneko S
    Int J Hematol; 2021 Nov; 114(5):572-579. PubMed ID: 32705572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
    Yilmaz A; Cui H; Caligiuri MA; Yu J
    J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.